Ustekinumab is a human monoclonal antibody that blocks interleukin (IL)-12 and IL-23, 2 cytokines that play an important role in the pathogenesis of psoriasis.1,2 It was approved in 2009 for the treatment of adult moderate to severe chronic plaque psoriasis. We report herein the first case to our knowledge of a patient with an eczematous eruption that appeared after the administration of ustekinumab.
Pernet C, Guillot B, Bessis D. Eczematous Drug Eruption After Ustekinumab Treatment. Arch Dermatol. 2012;148(8):959–960. doi:10.1001/archdermatol.2012.586
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: